Fluorescein is being used in over one million procedures each year in Europe and in the U.S. as a contrast agent for ophtalmic imaging procedures. Albufluor is a derivative of fluorescein, which displays superior pharmacokinetic properties by virtue of a stable non-covalent binding to serum albumin, making this product an ideal contrast agent for the imaging of vascular ocular defects.

The product, which derives from Philogen’s activity in DNA-encoded chemistry, has displayed an impressive performance in animal models and is scheduled to enter Phase II clinical trials in H2 2010.

SELECTED REFERENCES
Dumelin et al. (2008) Angew. Chem., 47, 3196-3201;

<< Pipeline